Artiva Biotherapeutics Amends 10-K to Complete Executive, Governance, and Ownership Disclosures
Summary
Artiva Biotherapeutics filed an amended 10-K to include previously omitted Part III information, detailing executive compensation, board structure, and ownership, while also disclosing multiple late insider trading reports.
Key Events
-
Completion of Annual Report
The filing amends the original 10-K from March 10, 2026, to include all required Part III information, which was previously omitted, providing a complete annual disclosure.
-
Executive Compensation Details
Provides comprehensive compensation data for named executive officers for 2025 and 2024, including base salaries, performance bonuses, and equity awards, with CEO Fred Aslan's total compensation at $6.67 million in 2025.
-
Late Insider Trading Reports
Discloses that six executive officers, including the CEO, had delinquent Section 16(a) reports in 2025, indicating a lapse in compliance with reporting requirements.
-
Significant Institutional Ownership
Highlights major institutional holders, with RA Capital and affiliates owning 39.9% and GC Corp. and affiliates holding 18.5% of common stock as of March 31, 2026.
Analysis
This 10-K/A filing completes the previously incomplete Annual Report on Form 10-K filed on March 10, 2026, by adding critical Part III information regarding directors, executive officers, corporate governance, executive compensation, security ownership, and principal accounting fees. The amendment addresses a significant compliance gap, providing investors with a full picture of the company's leadership, compensation structures, and major shareholders. The disclosure of multiple late Section 16(a) reports by several executive officers indicates a lapse in internal compliance, which is a negative signal. Additionally, the detailed equity compensation plans reveal substantial potential future dilution from authorized shares, which could impact shareholder value.
At the time of this filing, ARTV was trading at $9.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $253.1M. The 52-week trading range was $1.47 to $14.53. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.